Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 994 across all filing types
Latest filing 2013-03-27 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a new drug application submission to the FDA. The document length is short (1972 characters) and it primarily serves as an announcement of a press release rather than containing detailed financial data or comprehensive report content. Form 6-K filings are typically regulatory filings for current reports and announcements by foreign issuers. Therefore, this document fits best under Regulatory Filings (RNS) as it does not contain a full report, financial statements, or detailed management discussion.
2013-03-27 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release about receiving positive feedback from a scientific advice meeting regarding a marketing application plan. The document is short (2018 characters) and primarily serves as an announcement of this event rather than a detailed financial report or regulatory filing. It does not contain financial statements, audit information, or detailed management discussion. It is not an annual or interim report, nor a call transcript or governance document. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-03-19 English
FORM 6-K
Investor Presentation Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., with the SEC. It announces that the CEO will present an overview of the company at the 25th Annual ROTH Conference and provides a link to the presentation on the company's website. The document is short (1865 characters) and does not contain any financial statements or detailed financial data. It is essentially an announcement about an upcoming investor presentation and the availability of the presentation material online. According to the rules, such announcements about presentations or events are classified as Investor Presentation (IP) filings, especially since it references a presentation to be made and provides a link to it. It is not the presentation itself but an official announcement of it, which fits the Investor Presentation category better than others. Therefore, the classification is Investor Presentation (IP) with high confidence.
2013-03-13 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a presentation at a conference, but does not contain financial statements or detailed financial data. The document length is short (1930 characters), and it primarily serves as a regulatory announcement rather than a full report. According to the rules, such filings that do not contain substantive financial data and serve as announcements or regulatory updates should be classified as Regulatory Filings (RNS).
2013-03-06 English
FORM 20-F/A
Annual Report FY 2012
2013-03-04 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release update on development progress and planned NDA submission, but does not contain comprehensive financial statements or detailed financial analysis. The document length is short (1989 characters), and it primarily serves as an announcement rather than a full report. According to the rules, Form 6-K filings are typically regulatory filings that provide updates but are not full annual or interim reports. Therefore, the appropriate classification is Regulatory Filings (RNS).
2013-02-25 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.